Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper by Daniel J. Drucker et al. published in Nature Cancer:
“Perspective Nature Cancer on GLP-1 medicines and cancer risk.
Reducing obesity can reduce cancer risk, but beyond that, GLP-1 receptors are expressed on certain cancer cells – could be good or bad.
Real world studies suggest lower incidence of some cancers. Overall, impact on inflammation, TME, and cancer risk needs closer study.”
Title: Glucagon-like peptide-1 medicines and cancer
Authors: Julian M. Yabut and Daniel J. Drucker.
You can read the full article in Nature Cancer.
More posts featuring Stephen Liu.